Tenax Therapeutics (TENX) to Post Earnings on Wednesday

Tenax Therapeutics (NASDAQ:TENX) will likely be releasing its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, July 31, 2026 at 7:30 AM ET.

Tenax Therapeutics (NASDAQ:TENX) last issued its earnings results on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03. On average, analysts expect Tenax Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tenax Therapeutics Trading Down 3.6%

NASDAQ TENX opened at $13.82 on Wednesday. The firm’s fifty day moving average price is $13.71 and its two-hundred day moving average price is $13.55. The firm has a market capitalization of $366.51 million, a P/E ratio of -9.34 and a beta of 0.93. Tenax Therapeutics has a 1 year low of $5.78 and a 1 year high of $19.40.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Tenax Therapeutics in a research report on Tuesday, June 30th. Canaccord Genuity Group assumed coverage on Tenax Therapeutics in a research note on Tuesday, July 28th. They set a “buy” rating and a $35.00 target price for the company. Evercore began coverage on Tenax Therapeutics in a report on Wednesday, July 22nd. They set an “outperform” rating and a $39.00 target price on the stock. Chardan Capital restated a “buy” rating and issued a $27.00 price target on shares of Tenax Therapeutics in a research note on Friday, July 31st. Finally, Guggenheim reaffirmed a “buy” rating and set a $40.00 price target (up from $34.00) on shares of Tenax Therapeutics in a report on Monday, June 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TENX. Perceptive Advisors LLC acquired a new stake in Tenax Therapeutics during the fourth quarter worth approximately $5,353,000. Diadema Partners LP acquired a new position in shares of Tenax Therapeutics in the fourth quarter valued at approximately $2,964,000. Sphera Funds Management LTD. acquired a new position in shares of Tenax Therapeutics in the fourth quarter valued at approximately $2,317,000. Marshall Wace LLP increased its stake in shares of Tenax Therapeutics by 68.2% during the fourth quarter. Marshall Wace LLP now owns 298,153 shares of the specialty pharmaceutical company’s stock worth $3,634,000 after purchasing an additional 120,944 shares during the period. Finally, Woodline Partners LP bought a new position in shares of Tenax Therapeutics during the third quarter worth approximately $671,000. 1.67% of the stock is owned by institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.